Allianz Asset Management
PTGX icon

Allianz Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Allianz Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Hold
9,600
– – ﹤0.01% 1827
2026
Q1 		$1.01M Sell
9,600
-3,400
-26% -$301K ﹤0.01% 1712
2025
Q4 		$1.14M Sell
13,000
-6,678
-34% -$547K ﹤0.01% 1684
2025
Q3 		$1.31M Sell
19,678
-2,622
-12% -$149K ﹤0.01% 1648
2025
Q2 		$1.23M Buy
22,300
+15,900
+248% +$763K ﹤0.01% 1620
2025
Q1 		$310K Sell
6,400
-4,600
-42% -$193K ﹤0.01% 2031
2024
Q4 		$425K Sell
11,000
-8,300
-43% -$362K ﹤0.01% 1912
2024
Q3 		$869K Buy
19,300
+8,200
+74% +$331K ﹤0.01% 1673
2024
Q2 		$385K Hold
11,100
– – ﹤0.01% 1911
2024
Q1 		$321K Buy
+11,100
New +$302K ﹤0.01% 1728
2023
Q2 		– Sell
-21,500
Closed -$495K – 2262
2023
Q1 		$495K Hold
21,500
– – ﹤0.01% 1901
2022
Q4 		$235K Buy
+21,500
New +$181K ﹤0.01% 1849
2022
Q3 		– Sell
-164,075
Closed -$1.3M – 2075
2022
Q2 		$1.3M Buy
164,075
+31,341
+24% +$379K ﹤0.01% 1582
2022
Q1 		$3.14M Sell
132,734
-2,059
-2% -$58K ﹤0.01% 1419
2021
Q4 		$4.61M Buy
134,793
+85,622
+174% +$2.71M ﹤0.01% 1271
2021
Q3 		$871K Sell
49,171
-25,089
-34% -$1.07M ﹤0.01% 2001
2021
Q2 		$3.33M Hold
74,260
– – ﹤0.01% 1281
2021
Q1 		$1.92M Hold
74,260
– – ﹤0.01% 1416
2020
Q4 		$1.5M Hold
74,260
– – ﹤0.01% 1383
2020
Q3 		$1.45M Sell
74,260
-1,530
-2% -$28.7K ﹤0.01% 1343
2020
Q2 		$1.34M Sell
75,790
-26,308
-26% -$330K ﹤0.01% 1747
2020
Q1 		$720K Buy
102,098
+30,097
+42% +$226K ﹤0.01% 1917
2019
Q4 		$507K Sell
72,001
-41,275
-36% -$410K ﹤0.01% 2431
2019
Q3 		$1.39M Sell
113,276
-10,814
-9% -$136K ﹤0.01% 1991
2019
Q2 		$1.5M Buy
124,090
+47,175
+61% +$522K ﹤0.01% 1998
2019
Q1 		$967K Buy
+76,915
New +$679K ﹤0.01% 2113

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allianz Asset Management's PTGX Position: Q2 2026 in Review

Allianz Asset Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 9,600 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Allianz Asset Management first reported a position in PTGX in Q1 2019 and has held it in 26 quarters since. The position peaked at $4.61M in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Allianz Asset Management held 9,600 shares of Protagonist Therapeutics worth $1.01M as of Q2 2026.
  • Allianz Asset Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1827 holding.
  • Allianz Asset Management first reported a position in Protagonist Therapeutics in Q1 2019 and has held it in 26 quarters since.
  • Allianz Asset Management's Protagonist Therapeutics position peaked at $4.61M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.